[Effect of preoperative intra-arterial infusion of adriamycin on locally advanced breast cancer]. 1985

T Morimoto, and H Yamamoto, and T Yamakawa, and N Mitsuyama, and K Inui, and K Komaki, and A Umemoto, and T Akaiwa, and Y Monden

The effect of adriamycin (ADM) infused intraarterially as a preoperative procedure was analyzed retrospectively in 15 patients with primary advanced breast cancer. A high clinical response rate (CR+ PR) of 73% (11/15) was obtained by the treatment, and also remarkable degenerative changes of tumor cells were histologically noted in 10 out of 15 surgical specimens (67%). A correlation between the dose of ADM infused and the rate of tumor regression was observed. A significantly higher concentration of ADM was detected in metastatic lymph nodes and tumors obtained 3-4 weeks after intra-arterial infusion of ADM than that in normal mammary gland. As for side effects, alopecia, leukocytopenia, anorexia, nausea and vomiting occurred at high frequencies. The side effects due to this treatment were considered to be tolerable. Prognostically, a good survival rate was not observed using preoperative treatment with intra-arterial ADM infusion.

UI MeSH Term Description Entries
D007261 Infusions, Intra-Arterial Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease. Infusions, Regional Arterial,Infusions, Intra Arterial,Infusions, Intraarterial,Arterial Infusion, Intra,Arterial Infusion, Regional,Arterial Infusions, Intra,Arterial Infusions, Regional,Infusion, Intra Arterial,Infusion, Intra-Arterial,Infusion, Intraarterial,Infusion, Regional Arterial,Intra Arterial Infusion,Intra Arterial Infusions,Intra-Arterial Infusion,Intra-Arterial Infusions,Intraarterial Infusion,Intraarterial Infusions,Regional Arterial Infusion,Regional Arterial Infusions
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

T Morimoto, and H Yamamoto, and T Yamakawa, and N Mitsuyama, and K Inui, and K Komaki, and A Umemoto, and T Akaiwa, and Y Monden
November 1983, Gan to kagaku ryoho. Cancer & chemotherapy,
T Morimoto, and H Yamamoto, and T Yamakawa, and N Mitsuyama, and K Inui, and K Komaki, and A Umemoto, and T Akaiwa, and Y Monden
December 1984, Gan to kagaku ryoho. Cancer & chemotherapy,
T Morimoto, and H Yamamoto, and T Yamakawa, and N Mitsuyama, and K Inui, and K Komaki, and A Umemoto, and T Akaiwa, and Y Monden
November 1975, Cancer,
T Morimoto, and H Yamamoto, and T Yamakawa, and N Mitsuyama, and K Inui, and K Komaki, and A Umemoto, and T Akaiwa, and Y Monden
June 1988, Gan to kagaku ryoho. Cancer & chemotherapy,
T Morimoto, and H Yamamoto, and T Yamakawa, and N Mitsuyama, and K Inui, and K Komaki, and A Umemoto, and T Akaiwa, and Y Monden
February 1988, Gan to kagaku ryoho. Cancer & chemotherapy,
T Morimoto, and H Yamamoto, and T Yamakawa, and N Mitsuyama, and K Inui, and K Komaki, and A Umemoto, and T Akaiwa, and Y Monden
October 1988, Gan to kagaku ryoho. Cancer & chemotherapy,
T Morimoto, and H Yamamoto, and T Yamakawa, and N Mitsuyama, and K Inui, and K Komaki, and A Umemoto, and T Akaiwa, and Y Monden
August 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
T Morimoto, and H Yamamoto, and T Yamakawa, and N Mitsuyama, and K Inui, and K Komaki, and A Umemoto, and T Akaiwa, and Y Monden
August 1993, Gan to kagaku ryoho. Cancer & chemotherapy,
T Morimoto, and H Yamamoto, and T Yamakawa, and N Mitsuyama, and K Inui, and K Komaki, and A Umemoto, and T Akaiwa, and Y Monden
April 1985, Nihon Gan Chiryo Gakkai shi,
T Morimoto, and H Yamamoto, and T Yamakawa, and N Mitsuyama, and K Inui, and K Komaki, and A Umemoto, and T Akaiwa, and Y Monden
January 1995, Postgraduate medical journal,
Copied contents to your clipboard!